Table 3.
Best overall responses in patients analyzed for efficacy
| Group 1 (N = 29) n (%) |
Group 2 (N = 6) n (%) |
|
|---|---|---|
| Best overall responsea | ||
| CR | 22 (75.9) | 3 (50.0) |
| PR | 5 (17.2) | 1 (16.7) |
| SD | 1 (3.4) | 0 (0.0) |
| PD | 1 (3.4) | 2 (33.3) |
| NE | 0 (0.0) | 0 (0.0) |
| ORRb | 27 (93.1) | 4 (66.7) |
| 95% CI, %c | 77.2–99.2 | 22.3–95.7 |
| CR rate | 22 (75.9) | 3 (50.0) |
| 95% CI, %c | 56.5–89.7 | 11.8–88.2 |
N number of patients, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, CI confidence interval
aAssessed in accordance with the revised response criteria for malignant lymphoma (Cheson et al. J Clin Oncol. 2007;25(5):579–86)
bThe number and rate of patients who were categorized as CR or PR
cThe precise 95% confidence interval based on binominal probability